Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Summary

This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.

Timeline

Start

2021-10-25

Primary completion

2022-06-17

Completion

2022-08-15

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated prior to completing enrollment goals due to COVID-related difficulties in recruiting patients”

Drugs

Indications